In Capital
VC Fund
Hangzhou, China
In Capital is a value-oriented, research-driven, independent-thinking venture capital firm.
- Total investments:
- 61
- Last investment:
- Lead investor:
- 26%
Last updated:
For AI agents: llms.txt
Industries In Capital invests in
Stages In Capital invests in
Countries In Capital invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Seed
- $142k–$4.5M
- Angel
- $425k–$10M
- Series A
- $1.5M–$12M
Investment Focus
Industry
- Software 6 (10%)
- Information Technology 6 (10%)
- E-Commerce 5 (8%)
- Consulting 4 (7%)
- Service Industry 4 (7%)
Stage
- Series A 22 (36%)
- Angel 20 (33%)
- Seed 11 (18%)
- Series B 4 (7%)
- Series D 2 (3%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Fang Kai
Director
|
Director | Total investments: 1 | Find email | |
Xiang Jianbiao
Founding Partner
|
Founding Partner | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Tianmu Turbine is a company specializing in the design, manufacturing, & validation of aircraft engines and low-altitude propulsion systems. | $14.8M / Angel / Jun 12, 2026 | ||
|
FrameLeap Technology
|
FrameLeap Technology is the focusing company on large-scale model applications for digital sales employees through a three-in-one architecture of application + model + infrastructure, it creates enterprise-level digital sales employees to drive business growth. | $10M / Angel / May 20, 2026 | |
| Danong Technology delivers food supply, group meals, fresh chains, smart agriculture, and school-enterprise services. | Seed / Dec 15, 2025 | ||
| Hygea Medical Technology is a oncology-focused biopharma company. Hygea’s solutions cater to cancer therapies targeting diseases in the lung, liver, breast, and kidney. Hygea will continue to develop its micro-invasive and Cryo-HITTM technology. | $14.6M / Series D / Feb 15, 2023 | ||
| Bliss Bio is a biopharmaceutical company focused on development of tumor targeting and immunotherapy drugs. | $14.8M / Series B / Jan 18, 2023 | ||
| Across the Stars is a product guidance solution provider. | Angel / Nov 25, 2022 | ||
| Experience Home XMPlus is a full-journey customer experience management SaaS system, which is suitable for the customer experience department, product department, operation department, customer service department, marketing department, etc. Conversion rate, repurchase rate and word-of-mouth recommendation increase profits and brand value. | Series A / Jun 27, 2022 | ||
| Fangyun Intelligence is industry's first digital and intelligent R&D performance management platform, combining R&D process data with AI algorithms, promotes the active implementation of corporate strategies. | $1.6M / Angel / Apr 13, 2022 | ||
| Gravity is a chip developer, focusing on semiconductor integrated circuits and 5G fields such as consumer electronics chips, information security chips, NFC/RF chips, etc. Gravity’s main products cover fast charging chips, smart audio chips, power management chips, NFC near-field communication chips and other fields. | Series A / Dec 30, 2021 | ||
| TeamCode is a toolchain that helps developers work collaboratively in the cloud, auto-generates, builds, and deploys the dev environment. | Angel / Dec 08, 2021 | ||
| See all 61 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Similar country
Featured in Investor Lists
Recommended lists
FAQ
What does In Capital invest in?
In Capital invests primarily in Software, Information Technology and E-Commerce startups, most often at Series A and Angel stage. Most of the 61 investments tracked by Shizune back companies in China. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is In Capital's check size?
In Capital typically joins rounds of $142k–$4.5M at Seed, $425k–$10M at Angel and $1.5M–$12M at Series A. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds In Capital participates in.
How do I contact In Capital?
Public channels for In Capital include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at In Capital?
The team at In Capital includes Fang Kai (Director) and Xiang Jianbiao (Founding Partner). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
